Atlas Trials

A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule as Second-line Treatment in Subjects With Advanced Biliary Cancer

Clinical trial NCT04809142 · UNKNOWN

Trial details

NCT number
NCT04809142
Sponsor
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Status
UNKNOWN
Phase
Phase 3
Study type
INTERVENTIONAL
Advanced Biliary Cancer
Start date
2021-02-04
Primary completion
2022-03-18
Enrollment
392

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.